

MEDNAX, INC.
RECONCILIATION OF INCOME FROM CONTINING OPERATIONS
TO FORWARD-LOOKING ADJUSTED EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO MEDNAX, INC.
(in thousands)
(Unaudited)

	Year Ended December 31, 2021
Income from continuing operations attributable to Mednax, Inc.	\$ 89,300
Interest expense	69,100
Gain on sale of building	(7,280)
Loss on early extinguishment of debt	14,532
Income tax provision	32,248
Depreciation and amortization expense	32,100
Transformational and restructuring related expenses	20,000
Adjusted EBITDA from continuing operations attributable to Mednax, Inc.	<u>\$ 250,000</u>

This reconciliation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on assumptions and assessments made by Mednax's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements in this reconciliation are made as of October 28, 2021 and Mednax undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in Mednax's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well Mednax's current reports on Form 8-K, filed with the Securities and Exchange Commission.